Search results for " disease progression"

showing 10 items of 81 documents

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection.

2017

Introduction RD1-based Interferon-γ Release Assays (IGRAs) cannot distinguish latent from active tuberculosis (TB) disease. Conversely, a positive response to heparin-binding haemagglutinin (HBHA)-based IGRAs, among TB-infected subjects, correlates with Mycobacterium tuberculosis (Mtb) containment and low risk of TB progression. The aim of this study was to characterize HBHA-immune responses in HIV-infected and uninfected subjects with active TB or latent TB infection (LTBI). Methods 49 subjects were prospectively enrolled: 22 HIV-uninfected (13 TB, 9 LTBI) and 27 HIV-infected (12 HIV-TB, 15 HIV-LTBI). Whole blood and peripheral blood mononuclear cells were stimulated with HBHA and RD1 anti…

Genetics and Molecular Biology (all)0301 basic medicineBacterial DiseasesRNA virusesCD4-Positive T-LymphocytesMalePhysiologylcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesPathology and Laboratory MedicineBiochemistryMemory T cellsWhite Blood CellsImmunodeficiency VirusesInterferonAnimal CellsImmune PhysiologyLectinsMedicine and Health SciencesProspective Studieslcsh:ScienceInnate Immune SystemMultidisciplinarybiologyT CellsInterleukinvirus diseasesMiddle AgedFlow Cytometry3. Good healthActinobacteriaInfectious DiseasesMedical MicrobiologyViral PathogensVirusesDisease ProgressionCytokinesFemaleCellular TypesPathogensmedicine.drugResearch ArticleAdultTuberculosisImmune CellsImmunologyCytotoxic T cellsEnzyme-Linked Immunosorbent AssayPeripheral blood mononuclear cellMicrobiologySettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAMycobacterium tuberculosis03 medical and health sciencesInterferon-gammaImmune systemAntigenRetrovirusesmedicineTuberculosisHumansMicrobial PathogensAdult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; Humans; Interferon-gamma; Lectins; Male; Middle Aged; Prospective Studies; Tuberculosis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Blood CellsBacteriaLentiviruslcsh:ROrganismsBiology and Life SciencesProteinsHIVCell BiologyMolecular Developmentbiology.organism_classificationmedicine.diseaseTropical DiseasesVirology030104 developmental biologyAgricultural and Biological Sciences (all)Immune SystemImmunologylcsh:QInterferonsCD8Mycobacterium TuberculosisDevelopmental BiologyPLoS ONE
researchProduct

B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure

2019

Aims In acute heart failure (AHF), relationships between changes in B-type natriuretic peptide (BNP) and worsening renal function (WRF) and its prognostic implications have not been fully determined. We investigated the relationship between WRF and a decrease in BNP with in-hospital and 1-year mortality in AHF. Methods and results The Acute Kidney Injury NGAL Evaluation of Symptomatic heart faIlure Study (AKINESIS) was a prospective, international, multicentre study of AHF patients. Severe WRF (sWRF) was a sustained increase of >= 44.2 mu mol/L (0.5 mg/dL) or >= 50% in creatinine, non-severe WRF (nsWRF) was a non-sustained increase of >= 26.5 mu mol/L (0.3 mg/dL) or >= 50% in cr…

InotropeMaleTime Factorsmedicine.medical_treatmentWorsening renal function030204 cardiovascular system & hematologyKidneyKidney Function TestsRISK STRATIFICATIONchemistry.chemical_compound0302 clinical medicineAcute heart failure; B-type natriuretic peptide; Mortality; Worsening renal function; Acute Disease; Acute Kidney Injury; Aged; Biomarkers; Creatinine; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Natriuretic Peptide Brain; Prognosis; Prospective Studies; Time FactorsNatriuretic Peptide BrainNatriuretic peptideProspective StudiesDISCHARGEAcute kidney injuryBrainAcute Kidney InjuryPrognosis3. Good healthDERIVATIONHOSPITALIZATIONCreatinineAcute DiseaseCardiologyDisease ProgressionFemaleCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsGlomerular Filtration RateVENOUS CONGESTIONmedicine.medical_specialtymedicine.drug_classRenal functionPRESSUREVALIDATION03 medical and health sciencesNatriuretic PeptideInternal medicinemedicineHumansRenal replacement therapycardiovascular diseasesAgedMechanical ventilationHeart FailureCreatininebusiness.industryMORTALITYAcute heart failuremedicine.diseasechemistryB-type natriuretic peptideHeart failurebusinessBiomarkersFollow-Up Studies
researchProduct

Combined inguinal hernia in the elderly. Portraying the progression of hernia disease

2016

Abstract Introduction Identification of a combined hernia is a common occurrence in the course of inguinal hernia repair. This type of protrusion disease seems to affect the elderly, in particular. Very few investigations have been carried out to ascertain the structural changes that occur in the groin affected by this clinical condition. Method Analysis of intraoperative findings of combined inguinal hernias evidenced in the elderly, from the most recent 100 groin hernia repair procedures carried out by a single operator, represents the basis of the article. Protrusions that presumably represent the forerunner of this type of hernia were also analyzed: double ipsilateral inguinal hernias c…

Ipsilateral herniaAdultMalemedicine.medical_specialtyHerniamedicine.medical_treatmentHernia InguinalDisease030230 surgery03 medical and health sciencesYoung Adult0302 clinical medicinemedicineHumansHerniaIn patientAge FactorHerniorrhaphyAgedAged 80 and overGroinbusiness.industryCombined herniaInguinal herniaAge FactorsGeneral MedicineMiddle Agedmedicine.diseaseHernia repairSurgeryInguinal herniaCombined hernia; Hernia; Inguinal hernia; Ipsilateral hernia; Adult; Age Factors; Aged; Aged 80 and over; Disease Progression; Female; Hernia Inguinal; Herniorrhaphy; Humans; Male; Middle Aged; Young Adult; SurgeryCombined hernia; Hernia; Inguinal hernia; Ipsilateral hernia; Surgerysurgical procedures operativemedicine.anatomical_structure030220 oncology & carcinogenesisDisease ProgressionFemaleSurgerybusinessInferior epigastric vesselsProgressive diseaseHuman
researchProduct

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution

2016

Chronic liver damage leads to pathological accumulation of ECM proteins (liver fibrosis). Comprehensive characterization of the human ECM molecular composition is essential for gaining insights into the mechanisms of liver disease. To date, studies of ECM remodeling in human liver diseases have been hampered by the unavailability of purified ECM. Here, we developed a decellularization method to purify ECM scaffolds from human liver tissues. Histological and electron microscopy analyses demonstrated that the ECM scaffolds, devoid of plasma and cellular components, preserved the three-dimensional ECM structure and zonal distribution of ECM components. This method has been then applied on 57 l…

Liver Cirrhosis0301 basic medicineProteomicsPathologyProteomeBiopsylcsh:MedicineHepacivirusMatrix (biology)ProteomicsBiochemistryExtracellular matrixMiceLiver disease0302 clinical medicineFibrosisSettore BIO/13 - Biologia ApplicataMedicine and Health Scienceslcsh:Scienceliver fibrosisExtracellular Matrix ProteinsMultidisciplinaryDecellularizationAnimals; Extracellular Matrix; Hepacivirus; Humans; Liver; Liver Cirrhosis; Mice; Proteome; Proteomics; Tissue Scaffolds; Disease ProgressionTissue ScaffoldsChemistryLiver DiseasesLiver030220 oncology & carcinogenesisProteomeDisease ProgressionCellular Structures and OrganellesAnatomyliver fibrosis; extracellular matrix; proteomicsResearch Articlemedicine.medical_specialtyHistologySettore BIO/06extracellular matrixSurgical and Invasive Medical ProceduresGastroenterology and HepatologyScaffold03 medical and health sciencesmedicineAnimalsHumansHuman liverlcsh:RBiology and Life SciencesProteinsCell Biologymedicine.diseaseFibrosisLiver Fibrosi030104 developmental biologyLiver Fibrosis; Scaffold; Proteomicslcsh:QCollagensDevelopmental Biology
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct

Coagulation and fibrosis in chronic liver disease.

2008

In the hepatic tissue repair mechanism, hepatic stellate cells (HSCs) are recruited at the site of injury and their changes reflect paracrine stimulation by all neighbouring cell types, including sinusoidal endothelial cells, Kupffer cells, hepatocytes, platelets and leucocytes. Thrombin converts circulating fibrinogen to fibrin, promotes platelet aggregation, is a potent activator of endothelial cells, acts as a chemoattractant for inflammatory cells and is a mitogen and chemoattractant for fibroblasts and vascular smooth muscle cells. Most of the cellular effects elicited by thrombin are mediated via a family of widely expressed G-protein-coupled receptors termed protease activated recept…

Liver CirrhosisMaleKupffer CellsReceptors Proteinase-ActivatedThrombin liver fibrosisProteinase-ActivatedChronic liver diseaseFibrinLiver diseaseThrombinFibrosisReceptorsHepatic Stellate CellsmedicineAnimalsHumansPlateletReceptorBlood CoagulationWound HealingAnimals; Anticoagulants; Blood Coagulation; Chronic Disease; Disease Progression; Endothelial Cells; Female; Hepatic Stellate Cells; Hepatocytes; Humans; Kupffer Cells; Liver Cirrhosis; Liver Diseases; Male; Rats; Receptors Proteinase-Activated; Receptors Thrombin; Thrombin; Wound Healing; Gastroenterologybiologybusiness.industryLiver DiseasesThrombinGastroenterologyAnticoagulantsEndothelial Cellsmedicine.diseaseRatsChronic DiseaseImmunologyDisease ProgressionHepatocytesbiology.proteinHepatic stellate cellCancer researchFemaleReceptors Thrombinbusinessmedicine.drug
researchProduct

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease.

2008

Background & Aims: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children. Methods: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively. Results: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon α. Ten years after putative exposure, the outcome in …

Liver CirrhosisMaleTime FactorsHepacivirusHepacivirusChronic hepatitis CGastroenterologyLiver diseaseViralProspective StudiesChronicProspective cohort studyChildChildrenchronic epatitis C; long term course; childrenbiologyHazard ratioGastroenterologyHepatitis CViral LoadHepatitis CTreatment OutcomeItalyChild PreschoolHCVDisease ProgressionRNA ViralFemaleViral loadmedicine.medical_specialtyAdolescentGenotypeAlpha interferonSocio-culturaleViremiaAntiviral AgentsRisk AssessmentHEPATITISInternal medicinemedicineHumansViremiaAdolescent; Antiviral Agents; Child; Child Preschool; Disease Progression; Female; Genotype; Hepatitis C Chronic; Humans; Infant; Interferon-alpha; Italy; Liver Cirrhosis; Male; Proportional Hazards Models; Prospective Studies; RNA Viral; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; Viral Load; Viremia; Hepacivirus; GastroenterologyPreschoolProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryLong-term courseInfantInterferon-alphaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseImmunologyRNAbusinessGastroenterology
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy

2013

Abstract Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically used to treat anemia in patients with cancer receiving chemotherapy. After clinical trials reporting increased adverse events and/or reduced survival in ESA-treated patients, concerns have been raised about the potential role of ESAs in promoting tumor progression, possibly through tumor cell stimulation. However, evidence is lacking on the ability of EPO to directly affect cancer stem–like cells, which are thought to be responsible for tumor progression and relapse. We found that breast cancer stem–like cells (BCSC) isolated from patient tumors express the EPO receptor and respond to …

MAPK/ERK pathwayOncologyCancer Researchmedicine.medical_treatmentFluorescent Antibody TechniqueApoptosisMice SCIDImmunoenzyme TechniquesMiceCell MovementMice Inbred NODhemic and lymphatic diseasesTumor Cells CulturedCulturedBlottingAnemiaFlow CytometryTumor CellsTRIALSOncologyDisease ProgressionNeoplastic Stem CellsFemaleWesternSignal Transductionmedicine.drugSTIMULATING AGENTSEXPRESSIONmedicine.medical_specialtyBlotting WesternAntineoplastic AgentsBreast NeoplasmsSCIDRECOMBINANT-HUMAN-ERYTHROPOIETIN STIMULATING AGENTS EXPRESSION MORTALITY TRIALS ANEMIA ALPHA ALDH1Breast cancerIn vivoInternal medicinemedicineAnimalsHumansBreast cancer Cancer stem cellsALDH1ErythropoietinProtein kinase BCell ProliferationSettore MED/04 - Patologia GeneraleChemotherapybusiness.industryMORTALITYCancerRECOMBINANT-HUMAN-ERYTHROPOIETINmedicine.diseaseALPHAErythropoietinTumor progressionInbred NODAnemia; Animals; Antineoplastic Agents; Apoptosis; Blotting Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Disease Progression; Erythropoietin; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice Inbred NOD; Mice SCID; Neoplastic Stem Cells; Signal Transduction; Tumor Cells Cultured; Cancer Research; Oncologybusiness
researchProduct